These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37352576)

  • 21. Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
    Kong KM; Zhang JW; Liu BZ; Meng GR; Zhang Q
    Bioorg Med Chem Lett; 2020 Feb; 30(4):126901. PubMed ID: 31882299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
    Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
    Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors.
    Zhou J; Yu LZ; Fan YL; Guo CH; Lv XM; Zhou ZY; Huang HD; Miao DD; Zhang SP; Li XY; Zhao PP; Liu XP; Hu WH; Zhang C
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114860. PubMed ID: 36370550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation and comparison of the commonly used bioassays of human indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO).
    Zhang S; Guo L; Yang D; Xing Z; Li W; Kuang C; Yang Q
    Bioorg Chem; 2020 Nov; 104():104348. PubMed ID: 33142415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.
    Gao D; Li Y
    Bioorg Med Chem; 2017 Jul; 25(14):3780-3791. PubMed ID: 28526475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trial watch: IDO inhibitors in cancer therapy.
    Le Naour J; Galluzzi L; Zitvogel L; Kroemer G; Vacchelli E
    Oncoimmunology; 2020 Jun; 9(1):1777625. PubMed ID: 32934882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of secondary sulphonamides as IDO1 inhibitors with potent antitumour effects
    Ge S; Zhong H; Ma X; Zheng Y; Zou Y; Wang F; Wang Y; Hu Y; Li Y; Liu W; Guo W; Xu Q; Lai Y
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1240-1257. PubMed ID: 32466694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
    Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
    Front Immunol; 2021; 12():800630. PubMed ID: 35003126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation.
    Coluccia A; Passacantilli S; Famiglini V; Sabatino M; Patsilinakos A; Ragno R; Mazzoccoli C; Sisinni L; Okuno A; Takikawa O; Silvestri R; La Regina G
    J Med Chem; 2016 Nov; 59(21):9760-9773. PubMed ID: 27690429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
    Kim M; Tomek P
    Front Immunol; 2021; 12():636081. PubMed ID: 33708223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory investigation of niacin derivatives on metalloenzyme indoleamine 2,3-dioxygenase 1 for its immunomodulatory function.
    Yan D; Xu J; Tan X
    Metallomics; 2021 Feb; 13(3):. PubMed ID: 33638642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase*.
    Ortiz-Meoz RF; Wang L; Matico R; Rutkowska-Klute A; De la Rosa M; Bedard S; Midgett R; Strohmer K; Thomson D; Zhang C; Mebrahtu M; Guss J; Totoritis R; Consler T; Campobasso N; Taylor D; Lewis T; Weaver K; Muelbaier M; Seal J; Dunham R; Kazmierski W; Favre D; Bergamini G; Shewchuk L; Rendina A; Zhang G
    Chembiochem; 2021 Feb; 22(3):516-522. PubMed ID: 32974990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Research progress of indoleamine 2,3-dioxygenase inhibitors.
    Jiang T; Sun Y; Yin Z; Feng S; Sun L; Li Z
    Future Med Chem; 2015; 7(2):185-201. PubMed ID: 25686005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase.
    Yoshioka S; Ikeda T; Fukuchi S; Kawai Y; Ohta K; Murakami H; Ogo N; Muraoka D; Takikawa O; Asai A
    Int J Tryptophan Res; 2022; 15():11786469221138456. PubMed ID: 36467776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of a novel indoleamine 2,3-dioxigenase 1 (IDO1) and thioredoxin reductase (TrxR) dual inhibitor.
    Fan QZ; Zhou J; Zhu YB; He LJ; Miao DD; Zhang SP; Liu XP; Zhang C
    Bioorg Chem; 2020 Dec; 105():104401. PubMed ID: 33113415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activity.
    Tomek P; Palmer BD; Flanagan JU; Fung SP; Bridewell DJ; Jamie JF; Ching LM
    Anal Bioanal Chem; 2013 Mar; 405(8):2515-24. PubMed ID: 23314482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors.
    Yang R; Chen Y; Pan L; Yang Y; Zheng Q; Hu Y; Wang Y; Zhang L; Sun Y; Li Z; Meng X
    Bioorg Med Chem; 2018 Sep; 26(17):4886-4897. PubMed ID: 30170925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A patent review of IDO1 inhibitors for cancer.
    Cheong JE; Ekkati A; Sun L
    Expert Opin Ther Pat; 2018 Apr; 28(4):317-330. PubMed ID: 29473428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and Preliminary Cytotoxicity Studies of 1-[1-(4,5-Dihydrooxazol- 2-yl)-1H-indazol-3-yl]-3-phenylurea and 3-phenylthiourea Derivatives.
    Kornicka A; Saczewski F; Bednarski PJ; Korcz M; Szumlas P; Romejko E; Sakowicz A; Sitek L; Wojciechowska M
    Med Chem; 2017; 13(7):616-624. PubMed ID: 28266278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.